Zynerba hires new VP, chief financial officer

Zynerba Pharmaceuticals has appointed Richard Baron vice president and chief financial officer, the company said Monday.

Baron has more than 30 years of experience in executive finance leadership for early-stage, pharmaceutical and health care companies.

"Rick has an exemplary track record of successfully helping emerging companies grow to the next level through strategic financing," Zynerba Chairman and CEO Armando Anido said. "He will be a valued member of the Zynerba team as we rapidly approach clinical development of these novel transdermal synthetic cannabinoid candidates in the coming months and work to take the company to the next stage."

Zynerba prides itself on the development of innovative transdermal synthetic cannabinoid treatments using modern technology for patients with high, unmet medical needs.

Prior to joining Zynerba, Baron was senior vice president and CFO of Globus Medical, a medical device company with a market cap of more than $2 billion. Before that, he served as vice president of finance and CFO of Avid Radiopharmaceuticals, a biotech company that was sold to Eli Lilly in 2011 for $300 million. Baron also has been in CFO roles for a number of life sciences companies, including Animas Corporation, which was sold to Johnson & Johnson in 2007.

Baron earned his bachelor's in economics, with a concentration in accounting, from the Wharton School at the University of Pennsylvania.